Since the 1970s, acute myeloid leukemia (AML) subtypes have been classified by cellular variances under the microscope. In recent times, however, it has been discovered that AML's heterogeneity lies within the chromosomes as well. As an increasing amount of the disease's genetic variances are being discovered, it is clear that they have a significant prognostic effect on treatment response.